Format

Send to

Choose Destination
Immunol Rev. 2015 Nov;268(1):104-22. doi: 10.1111/imr.12342.

FcγR requirements leading to successful immunotherapy.

Author information

1
Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, General Hospital, Southampton, UK.

Abstract

Monoclonal antibody (mAb) immunotherapy is currently experiencing an unprecedented amount of success, delivering blockbuster sales for the pharmaceutical industry. Having experienced several false dawns and overcoming technical issues which limited progress, we are now entering a golden period where mAbs are becoming a mainstay of treatment regimes for diseases ranging from cancer to autoimmunity. In this review, we discuss how these mAbs are most likely working and focus in particular on the key receptors that they interact with to precipitate their therapeutic effects. Although their targets may vary, their engagement with Fcγ receptors (FcγRs) on numerous immune effector cells is almost universal, and here we review their roles in delivering successful immunotherapy.

KEYWORDS:

FcγR; anti-CD20; antibody therapy; immunomodulation; immunotherapy

PMID:
26497516
DOI:
10.1111/imr.12342
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center